Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School
Copyright 1992 The University of Chicago
Crossref reports the following articles citing this article:Kyung-Bok Son, Eui-Kyung Lee Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study, 39 (Jan 2022).Kazuhiro Takauchi, Tomomichi Mizuno Endogenous transport price, R&D spillovers, and trade, 78 (Oct 2021).Tianqin Shi, Nicholas C. Petruzzi, Dilip Chhajed The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy, 62 (Aug 2021).Frank R. Lichtenberg Are drug prices subject to creative destruction? Evidence from the US, 1997–2017, 30, no.88 (May 2021): 1910–1932.Alice M. Ellyson, Anirban Basu Do pharmaceutical prices rise anticipating branded competition?, 30, no.55 (Mar 2021): 1070–1081.Arjun Watane, Meghana Kalavar, Joshua Reyes, Nicolas A Yannuzzi, Jayanth Sridhar The Effect of Market Competition on the Price of Topical Eye Drops, (Mar 2021): 1–7.Colleen Cunningham, Florian Ederer, and Song Ma Killer Acquisitions, 129, no.33 (Feb 2021): 649–702.Yazed AlRuthia, Badr Aljohani, Wejdan R. Alsharif, Hala H. Alrasheed, Bushra M. Alghamdi, Shatha Asiri, Maryam Alarfaj, Ghadah S. Almuaythir, Saja Almazrou, Omar Almazroo, Ahmed Alaofi, Rawan Alenazi Prospects of Establishing a Saudi Version of the United States Food and Drug Administration Orange Book, 10, no.11 (Mar 2021): 120–125.Jihui Chen, Yi Wang The pricing effects of entry by Hainan airlines: Evidence from the U.S.-China international air travel market, 114 (Mar 2021): 105957.Isabel Correia, Luís Armada, Paula Veiga Generics competition in the Portuguese pharmaceutical market, 17, no.11 (Sep 2020): 17–28.Nami Kim, Eonsoo Kim, Jongseon Lee Innovating by eliminating: Technological resource divestiture and firms’ innovation performance, 123 (Feb 2021): 176–187.Junghee Lee, Hyun Seok (Huck) Lee, Hyoduk Shin, Vish Krishnan Alleviating Drug Shortages: The Role of Mandated Reporting Induced Operational Transparency, 93 (Jan 2021).Jerónimo Cajellas, Debi Prasad Mohapatra Welfare Effects of Public Procurement of Medicines: Evidence from Ecuador, (Dec 2020): 102697.David B. Ridley, Chung-Ying Lee Does Medicare Reimbursement Drive Up Drug Launch Prices?, 102, no.55 (Dec 2020): 980–993.Pedro Bento Quantifying the Effects of Patent Protection on Innovation, Imitation, Growth, and Aggregate Productivity, 0, no.00 (Aug 2020).Miguel González-Maestre, Lluís M. Granero Excessive vs. insufficient entry in spatial models: When product design and market size matter, 106 (Jul 2020): 27–35.Farasat A. S. Bokhari, Franco Mariuzzo, Arnold Polanski Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals, 29, no.33 (May 2020): 516–542.Yang Sun Index Fund Entry and Financial Product Market Competition, (May 2020).Archita Sarmah, Domenico De Giovanni, Pietro De Giovanni Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies, 282, no.33 (May 2020): 1053–1069.Chung-Ying Lee Pricing strategy and moral hazard: Copay coupons in pharmaceuticals, 70 (May 2020): 102611.Z. John Lu, William S. Comanor, Elliot Cherkas, Llad Phillips U.S. Pharmaceutical Markets: Expenditures, Health Insurance, New Products and Generic Prescribing from 1960 to 2016, 27, no.11 (Sep 2019): 1–26.Arzi Adbi, Ajay Bhaskarabhatla, Chirantan Chatterjee Stakeholder Orientation and Market Impact: Evidence from India, 161, no.22 (Jul 2018): 479–496.Sabrina Terrizzi, Chad Meyerhoefer ESTIMATES OF THE PRICE ELASTICITY OF SWITCHING BETWEEN BRANDED AND GENERIC DRUGS, 38, no.11 (Apr 2019): 94–108.Marco J. W. Kotschedoff, Max J. Pachali Higher Minimum Quality Standards and Redistributive Effects on Consumer Welfare, 39, no.11 (Jan 2020): 253–280.Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, Stuart Schweitzer The effect of patent expiration on sales of branded competitor drugs in a therapeutic class, 15, no.44 (Jul 2019): 177–184.Jacquelyn W. Chou, Alison R. Silverstein, Dana P. Goldman Short-term budget affordability of hepatitis C treatments for state Medicaid programs, 19, no.11 (Feb 2019).Yoshimi Harada, Shintaro Sengoku The Key Success Factors of Biotech Start-Up Firms: Characteristics and Attributes of the Management Teams of High-Performing Biotech Start-Ups, (Aug 2019): 1–15.Jennifer H. Mike A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines, 22, no.3-43-4 (Jul 2019): 162–204.Micki Eisenman, Srikanth Paruchuri Inventor knowledge recombination behaviors in a pharmaceutical merger: The role of intra-firm networks, 52, no.22 (Apr 2019): 189–201.Margaret E. Helmuth, Qian Liu, Marc N. Turenne, Jeong M. Park, Murewa Oguntimein, Sarah K. Dutcher, Rajesh Balkrishnan, Pratima Sharma, Jarcy Zee, Alan B. Leichtman, Abigail R. Smith Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States, 14, no.33 (Feb 2019): 421–430.Edward D. Perry, David A. Hennessy, GianCarlo Moschini Product concentration and usage: Behavioral effects in the glyphosate market, 158 (Feb 2019): 543–559.Andrew T. Ching, Manuel Ignacio Hermosilla, Qiang Liu Structural Models of the Prescription Drug Market, (Jan 2019).Pierre Dubois, Laura Lasio Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals, 108, no.1212 (Dec 2018): 3685–3724.Rajat Khanna, Isin Guler, Atul Nerkar Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry, 39, no.99 (Aug 2018): 2439–2465.Luke M. Olson, Brett W. Wendling Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity, 53, no.11 (Apr 2018): 139–172.Miguel González-Maestre, Lluís M. Granero Competition with targeted product design: Price, variety, and welfare, 59 (Jul 2018): 406–428.Onesun Steve Yoo, Rakesh Sarin Consumer Choice and Market Outcomes Under Ambiguity in Product Quality, 37, no.33 (Jun 2018): 445–468.Jörg Mahlich, Isao Kamae, Rosarin Sruamsiri Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment, 18, no.33 (Nov 2017): 339–348.Susan J. Méndez Parallel trade of pharmaceuticals: The Danish market for statins, 27, no.22 (Sep 2017): 333–356.Rajat Khanna, Isin Guler, Atul A. Nerkar Entangled Decisions: Knowledge Interdependencies and Terminations of Patented Inventions in the Pharmaceutical Industry, (Jan 2018).Atanu Saha Strategic Deterrence: An Application to Biologic Pharmaceuticals, (Jan 2018).Marco J.W. Kotschedoff, Max J. Pachali Higher Minimum Quality Standards and Redistributive Effects on Consumer Welfare, (Jan 2018).Colleen Cunningham, Florian Ederer, Song Ma Killer Acquisitions, (Jan 2018).John E. Thanassoulis The I.O. of Ethics and Cheating When Consumers Do Not Have Rational Expectations, (Jan 2018).Juan Pablo Atal, José Ignacio Cuesta, Morten Sæthre Quality Regulation and Competition: Evidence from Pharmaceutical Markets, (Jan 2018).Sharat Ganapati, Rebecca McKibbin Non-Tariff Barriers and Bargaining in Generic Pharmaceuticals, (Jan 2018).Yixin (Iris) Wang, Jun Li, Ravi Anupindi Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach, (Jan 2018).Wei-Han Cheng, Étienne Gaudette, Dana P. Goldman PCSK9 Inhibitors Show Value for Patients and the US Health Care System, 20, no.1010 (Dec 2017): 1270–1278.Mats A. Bergman, David Granlund, Niklas Rudholm Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals, 79, no.66 (Apr 2017): 969–996.Oana Mihaescu, Niklas Rudholm DEFINING RELEVANT MARKETS FOR PHARMACEUTICALS, 69, no.44 (Nov 2016): E126–E149.Carl Rudolf Blankart, Tom Stargardt Preferred supplier contracts in post-patent prescription drug markets, 20, no.33 (Feb 2016): 419–432.Daigo Fukumoto, Ai Tsuyuki, Takeshi Suzuki Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery Prices, 51, no.55 (Dec 2017): 597–603.Ali Bonakdar Tehrani, Norman V. Carroll The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act, 15, no.44 (Feb 2017): 513–520.Mikael Linden Price variability, generic substitution, market size and multimarket contacts in the Finnish beta blocker market, 44, no.22 (Nov 2016): 161–174.Mingyue Zhao, Jing Wu Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance, 17, no.33 (Nov 2016): 311–320.Leemore Dafny, Christopher Ody, Matt Schmitt When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization, 9, no.22 (May 2017): 91–123.Faris El-Dahiyat Pharmacoeconomic evidence and policies to promote use of generic medicines in Jordan, 19, no.1-21-2 (Apr 2017): 71–86.Cristina Zerbini, Donata Tania Vergura, Beatrice Luceri Consumers' intention to buy generic drugs: Evidences from the Italian setting, , no.11 (Mar 2017): 159–176.Vardan Avagyan, Vardit Landsman, Stefan Stremersch Marketing Models for the Life Sciences Industry, (Jul 2017): 385–430.Taehwan Kim Changing Market Conversion and Evolving Ways to Compete: Evidence from Retail Gasoline, (Jan 2017).Patrick Leoni, Alvaro Sandroni Can patent duration hinder medical innovation, 16, no.44 (Sep 2016): 397–406.Joan Costa-Font Is medicines parallel trade ‘regulatory arbitrage’?, 16, no.44 (Sep 2016): 321–336.Kurt R. Brekke, Chiara Canta, Odd Rune Straume Reference pricing with endogenous generic entry, 50 (Dec 2016): 312–329.Mohsen Ali Murshid, Zurina Mohaidin, Goh Yen Nee The influence patient’s characteristics “requests and expectations” on physician prescribing behavior, 10, no.44 (Nov 2016): 390–411.Katharina Elisabeth Fischer, Tom Stargardt The diffusion of generics after patent expiry in Germany, 17, no.88 (Nov 2015): 1027–1040.Lee Branstetter, Chirantan Chatterjee, Matthew J. Higgins Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry, 47, no.44 (Nov 2016): 857–890.Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte, Régis Renault Push-me pull-you: comparative advertising in the OTC analgesics industry, 47, no.44 (Nov 2016): 1029–1056.Chon Kit Chao, Hao Hu, Liming Zhang, Jihong Wu Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor, 7, no.33 (Oct 2016): 258–272.William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States, 108, no.77 (Mar 2016): djw003.Jianfei Guo, Christina Kelton Competition between Brand-Name and Generic Drugs, (May 2016): 181–193.Rajat Khanna, Isin Guler, Atul Nerkar Fail Often, Fail Big, and Fail Fast? Learning from Small Failures and R&D Performance in the Pharmaceutical Industry, 59, no.22 (Apr 2016): 436–459.Kerry M. Tan Incumbent Response to Entry by Low-Cost Carriers in the U.S. Airline Industry, 82, no.33 (Nov 2015): 874–892.Rena M. Conti, William V. Padula, Richard A. Larson Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU, (Aug 2016): 231–255.Susan J. Mendez Parallel Trade of Pharmaceuticals: The Danish Market for Statins, (Jan 2016).Hye-Young Kwon, Hyungmin Kim, Brian Godman, Michael R Reich The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs, 15, no.66 (Sep 2015): 1007–1014.Karen Van Nuys, Ronald Brookmeyer, Jacquelyn W. Chou, David Dreyfus, Douglas Dieterich, Dana P. Goldman Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern, 34, no.1010 (Oct 2015): 1666–1674.Panagiotis Petrou, Michael A. Talias Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market, 7 (Sep 2015): 67–73.Silvia Appelt Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry, 97, no.33 (Jul 2015): 654–666.Mee-Hyun Cho, Ki-Bong Yoo, Hoo-Yeon Lee, Kwang-Sig Lee, Jeoung A Kwon, Kyu-Tae Han, Jae-Hyun Kim, Eun-Cheol Park The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea, 119, no.55 (May 2015): 604–611.Osamu Takizawa, Hisashi Urushihara, Shiro Tanaka, Koji Kawakami Price difference as a predictor of the selection between brand name and generic statins in Japan, 119, no.55 (May 2015): 612–619.Kathleen Iacocca, James Sawhill, Yao Zhao Why brand drugs priced higher than generic equivalents, 9, no.11 (Apr 2015): 3–19.Rena M. Conti, William V. Padula, Richard A. Larson Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU, 94, no.S2S2 (Mar 2015): 249–257.Zoulikha Snoussi Tarif de référence et entrée des génériques : l’impact sur les prix des médicaments en Algérie, , no.149149 (Mar 2015): 103–147.Shanjun Li, Ramanan Laxminarayan Are Physicians' Prescribing Decisions Sensitive to Drug Prices? Evidence from a Free-antibiotics Program, 24, no.22 (Oct 2013): 158–174.Kurt Richard Brekke, Chiara Canta, Odd Rune Straume Reference Pricing with Endogenous Generic Entry, (Jan 2015).Kurt Richard Brekke, Chiara Canta, Odd Rune Straume Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform., (Jan 2015).Rajat Khanna, Isin Guler, Atul A. Nerkar Fail Often, Fail Big, and Fail Fast? Learning from Small Failures and R&D Performance in the Pharmaceutical Industry, (Jan 2015).Joan Costa-Font, Alistair McGuire, Nebibe Varol Price regulation and relative delays in generic drug adoption, 38 (Dec 2014): 1–9.Panos Kanavos Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States, 118, no.22 (Nov 2014): 229–241.Brett Christophers On the Performativity of Pill Pricing: Theory and Reality in the Economics of Global Pharmaceuticalization, 46, no.44 (Feb 2014): 1054–1071.Dr. Vivek Pande, Yu Yu, Yi Zhao The effect of Affordable Care Act on the competition in the post-patent ethical drug market, 8, no.33 (Aug 2014): 314–347.Fredric Blavin, Timothy Waidmann, Linda J. Blumberg, Jeremy Roth Trends in Prescription Drug Spending Leading Up to Health Reform, 71, no.44 (May 2014): 416–432.Ulrich Kaiser, Susan J. Mendez, Thomas Rønde, Hannes Ullrich Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark, 36 (Jul 2014): 174–187.Joan Costa-Font, Caroline Rudisill, Stefanie Tan Brand loyalty, patients and limited generic medicines uptake, 116, no.2-32-3 (Jun 2014): 224–233.Jaume Puig-Junoy, Beatriz González López-Valcárcel Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007, 116, no.2-32-3 (Jun 2014): 170–181.Sotiris Vandoros, Panos Kanavos Parallel Trade and Pharmaceutical Prices: A Game-theoretic Approach and Empirical Evidence from the European Union, 37, no.66 (Mar 2013): 856–880.Conceição Portela Reference pricing system in Portugal – Supply, demand, and the effect of reimbursement level, 7, no.22 (Jan 2014): 120–126.Yu Yu, Sachin Gupta Pioneering advantage in generic drug competition, 8, no.22 (May 2014): 126–150.Sotiris Vandoros THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS, 23, no.55 (May 2013): 621–630.Steven Tenn, Brett W Wendling Entry Threats and Pricing in the Generic Drug Industry, 96, no.22 (May 2014): 214–228.Christina M. L. Kelton, Lenisa V. Chang, Jeff J. Guo, Yan Yu, Edmund A. Berry, Boyang Bian, Pamela C. Heaton Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008, 12, no.22 (Feb 2014): 165–177.Jing Wu, Judy Xu, Gordon Liu, Jiuhong Wu Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals, 32, no.33 (Nov 2013): 293–303.SOUMYANANDA DINDA, ARIJIT MUKHERJEE A Note on the Adverse Effect of Competition on Consumers, 16, no.11 (Jun 2013): 157–163.Elina Petrova Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development, (Oct 2013): 19–81.Vardit Landsman, Isabel Verniers, Stefan Stremersch The Successful Launch and Diffusion of New Therapies, (Oct 2013): 189–223.Ya-Ming Liu, Chee-Ruey Hsieh Profit-Seeking Behavior of Medical Providers and Generic Competition in the Pharmaceutical Market: Evidence from Taiwan, 14, no.11 (Nov 2013): 241–275.Miguel GonzzlezzMaestre, Luis M. Granero Competition with Targeted Product Design: Price, Variety, and Welfare, (Jan 2014).Patrick L. Leoni The Economics of an HIV/AIDS Vaccine, (Jan 2014).Andrey Shastitko, Svetlana Golovanova, Alexander Kurdin, Vadim Novikov, Natalia Pavlova (Macroeconomic Effects of Competition Restrictions), (Jan 2014).Charles Courtemanche, Art Carden Competing with Costco and Sam's Club: Warehouse Club Entry and Grocery Prices, 80, no.33 (Jan 2014): 565–585.Makoto Kakinaka, Ryuta Ray Kato Regulated medical fee schedule of the Japanese health care system, 13, no.3-43-4 (Sep 2013): 301–317.Abby Alpert, Mark Duggan, Judith K. Hellerstein Perverse reverse price competition: Average wholesale prices and Medicaid pharmaceutical spending, 108 (Dec 2013): 44–62.Mary E. Schramm, Michael Y. Hu Perspective: The Evolution of R&D Conduct in the Pharmaceutical Industry, 30 (Sep 2013): 203–213.Antonio Cabrales, Sergi Jiménez-Martín THE DETERMINANTS OF PRICING IN PHARMACEUTICALS: ARE US PRICES REALLY SO HIGH?, 22, no.1111 (Jan 2013): 1377–1397.Saradindu Bhaduri, Thomas Brenner Examining the determinants of drug launch delay in pre-TRIPS India, 14, no.55 (Sep 2012): 761–773.Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte Information content of advertising: Empirical evidence from the OTC analgesic industry, 31, no.55 (Sep 2013): 355–367.Peter Arcidiacono, Paul B. Ellickson, Peter Landry, David B. Ridley Pharmaceutical followers, 31, no.55 (Sep 2013): 538–553.Kathleen Iacocca, James Sawhill, Yao Zhao A multiple regression model to explain the cost of brand-drugs, 47, no.33 (Sep 2013): 238–246.Rok Hren Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010), 2, no.22 (Sep 2013): 290–299.Roger Feldman, Félix Lobo Competition in prescription drug markets: the roles of trademarks, advertising, and generic names, 14, no.44 (Jul 2012): 667–675.Sotiris Vandoros, Panos Kanavos The generics paradox revisited: empirical evidence from regulated markets, 45, no.2222 (Aug 2013): 3230–3239.Kurt Richard Brekke, Tor Helge Holmås, Odd Rune Straume Margins and market shares: Pharmacy incentives for generic substitution, 61 (Jul 2013): 116–131.Eon van der Merwe Smit, Jhandré Bredenkamp Originator and generic medicine: pricing and market share, 7, no.22 (Jun 2013): 104–119.Farasat A. S. Bokhari, Gary M. Fournier Entry in the ADHD drugs market: Welfare impact of generics and me‐too's, 61, no.22 (Jul 2013): 339–392.Anandaroop Dasgupta, Kenneth A. Lawson Utilization of and expenditures for selective serotonin reuptake inhibitors (SSRIs) and factors associated with change in price per-prescription of brand SSRIs in the Texas Medicaid programme (1991-2009), 4, no.22 (Feb 2013): 105–113.Panos Kanavos, Alessandra Ferrario, Sotiris Vandoros, Gerard F. Anderson Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs, 32, no.44 (Apr 2013): 753–761.Omotayo Fatokun, Mohamed IM Ibrahim, Mohamed A Hassali Factors determining the post-patent entry of generic medicines in Malaysia: A survey of the Malaysian generic pharmaceutical industry, 10, no.11 (May 2013): 22–33.Thomas Friedli, Daniel Bellm A Look to the Environment and the Impact on OPEX, (Jul 2013): 77–102.Jean Spinks, Gang Chen, Lara Donovan Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy, 37, no.55 (Jan 2013): 675.Luke Olson, Brett W. Wendling Estimating the Effect of Entry on Generic Drug Prices Using Hatch-Waxman Exclusivity, (Jan 2013).Peter Arcidiacono, Paul B. Ellickson, Peter Landry, David B. Ridley Pharmaceutical Followers, (Jan 2013).Laura Birg Pharmaceutical Regulation and Health Policy Objectives, (Jan 2013).Andrey E Shastitko, Svetlana Golovanova, Polina Kryuchkova, Alexander Kurdin, Vadim Novikov, Natalia Pavlova : (Effects of Weak Competition: Quantitative Assessment and Policy Implications), (Jan 2013).Ya-Ming Liu, Jur-Shan Cheng Determinants of generic entry in the regulated Taiwanese prescription drug market, 108, no.2-32-3 (Dec 2012): 228–235.Inthira Yamabhai, Richard D Smith A review of the health and economic implications of patent protection, with a specific focus on Thailand, 10, no.11 (Aug 2012).Jason S Rotter, Douglas Foerster, John FP Bridges The changing role of economic evaluation in valuing medical technologies, 12, no.66 (Jan 2014): 711–723.Dean C.H. Wilkie, Lester W. Johnson, Lesley White Strategies used to defend pharmaceutical brands from generics, 46, no.99 (Sep 2012): 1195–1214.Dean C.H. Wilkie, Lester W. Johnson, Lesley White The impact of low-price brands on the order of entry advantage, 28, no.7-87-8 (Jul 2012): 957–973.Laurent Granier, Sébastien Trinquard Predation in off-patent drug markets, 44, no.1717 (Jun 2012): 2171–2186.Gautier Duflos, Frank R. Lichtenberg Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization, 32, no.11 (Mar 2012): 95–109.Ida Ferrara, Paul Missios Pricing of drugs with heterogeneous health insurance coverage, 31, no.22 (Mar 2012): 440–456.Darren Filson A Markov-perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry, 43, no.11 (Mar 2012): 110–138.Darius Lakdawalla and Tomas Philipson Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets, 55, no.11 (Jul 2015): 151–187.Jie Chen, John A. Rizzo Pricing dynamics and product quality: the case of antidepressant drugs, 42, no.11 (Dec 2010): 279–300.Joan-Ramón Borrell Regulación de los precios de los medicamentos: Tendencias recientes y cuestiones desatendidas al final del proceso, (Jan 2012): 93–109.Farasat A. S. Bokhari, Gary M. Fournier Entry in the ADHD Drugs Market: Welfare Impact of Generics and Me-Toos, (Jan 2012).Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte Information Content of Advertising: Empirical Evidence from the OTC Analgesic Industry, (Jan 2012).Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte, Regis Renault Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry, (Jan 2012).Ajay Bhaskarabhatla, Chirantan Chatterjee First-Mover Advantage before and after TRIPS: Evidence from the Indian Pharmaceutical Industry, (Jan 2012).Roger Bate, Ginger Zhe Jin, Aparna Mathur Does price reveal poor-quality drugs? Evidence from 17 countries, 30, no.66 (Dec 2011): 1150–1163.Yu-Wen Wen, Weng-Foung Huang, Yue-Chune Lee, Ken N Kuo, Chia-Rung Tsai, Yi-Wen Tsai Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes, 11, no.11 (Jan 2011).Fritz von der Schulenburg, Sotiris Vandoros, Panos Kanavos The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors, 1, no.11 (Nov 2011).Simon P Anderson, Joshua S Gans Platform Siphoning: Ad-Avoidance and Media Content, 3, no.44 (Nov 2011): 1–34.Kurt R. Brekke, Tor Helge Holmas, Odd Rune Straume Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment, 95, no.7-87-8 (Aug 2011): 624–638.M. Joseph Sirgy, Dong-Jin Lee, Grace B. Yu Consumer Sovereignty in Healthcare: Fact or Fiction?, 101, no.33 (Jan 2011): 459–474.Panos G. Kanavos, Sotiris Vandoros Determinants of branded prescription medicine prices in OECD countries, 6, no.33 (May 2011): 337–367.Ernst R. Berndt An Overview of Henry Grabowski’s Scholarly Contributions, 18, no.22 (Jul 2011): 151–154.Ernst R. Berndt, Nathan Blalock, Iain M. Cockburn Diffusion of New Drugs in the Post-TRIPS Era, 18, no.22 (Jul 2011): 203–224.Maria Cristina Odasso, Elisa Ughetto Patent-backed securities in pharmaceuticals: what determines success or failure?, 41, no.33 (May 2011): 219–239.Shamindra Nath Sanyal, Saroj Kumar Datta The effect of country of origin on brand equity: an empirical study on generic drugs, 20, no.22 (Apr 2011): 130–140.David Granlund, Niklas Rudholm Consumer Information and Pharmaceutical Prices: Theory and Evidence*, 73, no.22 (Nov 2010): 230–254.Dag Morten Dalen, Kari Furu, Marilena Locatelli, Steinar Strøm Generic substitution: micro evidence from register data in Norway, 12, no.11 (Mar 2010): 49–59.Antara Dutta From Free Entry to Patent Protection: Welfare Implications for the Indian Pharmaceutical Industry, 93, no.11 (Feb 2011): 160–178.Glenn Ellison, Sara Fisher Ellison Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration, 3, no.11 (Feb 2011): 1–36.Joan-Ramón Borrell Drug Price Regulation: Recent Trends and Downstream Neglected Issues, (Jan 2011): 81–96.Simon P. Anderson, Joshua S. Gans Platform Siphoning: Ad-Avoidance and Media Content, (Jan 2011).Iván Moreno-Torres What If There Was a Stronger Pharmaceutical Price Competition in Spain? When Regulation Has a Similar Effect to Collusion, (Jan 2011).Iván Moreno-Torres Generic Drugs in Spain: Price Competition versus Moral Hazard, (Jan 2011).Patrick L. Leoni, Alvaro Sandroni Can Patent Duration Hinder Medical Innovation for Neglected Diseases?, (Jan 2011).Michael J. Moore, Edward A. Snyder, James W. Hughes Napsterizing Pharmaceuticals: Access, Innovation, and Welfare, (Jan 2011).Kerry M. Tan Incumbent Response to Entry by Low-Cost Carriers in the U.S. Airline Industry, (Jan 2011).Martin Hoyle Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis, 29, no.11 (Jan 2011): 1–15.David Granlund Price and welfare effects of a pharmaceutical substitution reform, 29, no.66 (Dec 2010): 856–865.Kurt W. Rotthoff Product liability litigation: an issue of Merck and lawsuits over Vioxx, 20, no.2424 (Dec 2010): 1867–1878.Andrew T. Ching Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration, 28, no.66 (Nov 2010): 619–638.Andrew T. Ching A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*, 51, no.44 (Nov 2010): 1175–1207.Darren Filson, Ahmed Oweis The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry, 29, no.44 (Jul 2010): 575–584.Jörgen Hellström, Niklas Rudholm Uncertainty in the generic versus brand name prescription decision, 38, no.33 (Mar 2009): 503–521.Yi-Wen Tsai, Yu-Wen Wen, Weng-Foung Huang, Ken N. Kuo, Pei-Fen Chen, Hsin-Wei Shih, Yue-Chune Lee Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes, 11, no.33 (Aug 2009): 279–290.Darius N. Lakdawalla, Eric C. Sun, Anupam B. Jena, Carolina M. Reyes, Dana P. Goldman, Tomas J. Philipson An economic evaluation of the war on cancer, 29, no.33 (May 2010): 333–346.Panos Kanavos, Sotiris Vandoros Competition in prescription drug markets: is parallel trade the answer?, 58 (Jan 2010): n/a–n/a.Ian McCarthy Chapter 10 A Survey on the Economics of the U.S. Pharmaceutical Industry, (Mar 2015): 201–241.Adam Gailey, Darius Lakdawalla, Neeraj Sood Patents, innovation, and the welfare effects of Medicare Part D, (Mar 2015): 317–344.Kensuke Kubo Inferring the Effects of Vertical Integration from Entry Games: An Analysis of the Generic Pharmaceutical Industry, (Jan 2010).Steven Tenn, Brett W. Wendling Entry Threats and Pricing in the Generic Drug Industry, (Jan 2010).Kurt Richard Brekke, Tor Helge Holmas, Odd Rune Straume Margins and Market Shares: Pharmacy Incentives for Generic Substitution, (Jan 2010).Claudio Lucarelli, Sean Nicholson, Minjae Song Bundling Among Rivals: A Case of Pharmaceutical Cocktails, (Jan 2010).Ulrich Kaiser, Susan J. Mendez, Thomas Rønde Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark, (Jan 2010).Laurent Granier, Sebastien Trinquard Predation in Off-Patent Drug Markets, (Jan 2010).George W. Pasdirtz Controlling direct-to-consumer advertising, professional promotion and the price of pharmaceutical drugs, (Dec 2009): 2096–2106.KIMTAEGI, Keun-Yeob Oh The Effects of KOR-US FTA on the Patents of Korean Pharmaceutical Industry, 15, no.33 (Dec 2009): 197–223.Eleftherios Zacharias Firm entry, product repositioning and welfare, 49, no.44 (Nov 2009): 1225–1235.Matthew J. Higgins, Stuart J. H. Graham Balancing Innovation and Access: Patent Challenges Tip the Scales, 326, no.59515951 (Oct 2009): 370–371.Kurt R. Brekke, Odd Rune Straume Pharmaceutical Patents: Incentives for Research and Development or Marketing?, 76, no.22 (Oct 2009): 351–374.John A. Rizzo, Richard Zeckhauser Generic script share and the price of brand-name drugs: the role of consumer choice, 9, no.33 (Jan 2009): 291–316.Sung-Hwan Kim Predatory reputation in US airline markets, 27, no.55 (Sep 2009): 592–604.Stefan Stremersch, Walter Van Dyck Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field, 73, no.44 (Jul 2009): 4–30.Iván Moreno-Torres, Jaume Puig-Junoy, Joan-Ramon Borrell Generic Entry into the Regulated Spanish Pharmaceutical Market, 34, no.44 (Jul 2009): 373–388.Ying Kong Competition between brand-name and generics - analysis on pricing of brand-name pharmaceutical, 18, no.55 (May 2009): 591–606.Kurt R. Brekke, Astrid L. Grasdal, Tor Helge Holmås Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?, 53, no.22 (Feb 2009): 170–185.Kevin C. Green Competition in the Pharmaceutical Industry: The Case of PAH Drugs, 16, no.11 (Feb 2009): 55–71.Kurt W. Rotthoff Product Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx, (Jan 2009).John A. Vernon, A. Bennett, Joseph H. Golec Exploration of Potential Economics of Follow-On Biologics and Implications for Data Exclusivity Periods for Biologics, (Jan 2009).Dag Morten Dalen, Kari Furu, Marilena Locatelli, Steinar Strom Generic Substitution - Micro Evidence from Register Data in Norway, (Jan 2009).Yongmin Chen, Michael H. Riordan Price-increasing competition, 39, no.44 (Dec 2008): 1042–1058.Marin C Gemmill, Sarah Thomson, Elias Mossialos What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries, 7, no.11 (May 2008).Suchin Virabhak, Wook Sohn Drug competition and voluntary exit, 101, no.11 (Oct 2008): 34–37.Ida Ferrara, Ying Kong Can health insurance coverage explain the generic competition paradox?, 101, no.11 (Oct 2008): 48–52.Gail B. Rattinger, Rahul Jain, Jing Ju, C. Daniel Mullins Principles of Economics Crucial to Pharmacy Students' Understanding of the Prescription Drug Market, 72, no.33 (Sep 2008): 61.Panos Kanavos, Joan Costa-Font, Elizabeth Seeley Competition in off-patent drug markets: Issues, regulation and evidence, 23, no.5555 (Jul 2008): 499–544.Tomas Philipson, Ernst R. Berndt, Adrian H.B. Gottschalk, Eric Sun Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts, 92, no.5-65-6 (Jun 2008): 1306–1325.Michael Adriaen, Kristof De Witte, Steven Simoens Pricing Strategies of Originator and Generic Medicines following Patent Expiry in Belgium, 5, no.33 (Apr 2008): 175–187.DAVID S. EVANS, MICHAEL A. SALINGER THE ROLE OF COST IN DETERMINING WHEN FIRMS OFFER BUNDLES, 56, no.11 (Mar 2008): 143–168.Tomas J Philipson, Eric Sun Is the Food and Drug Administration Safe and Effective?, 22, no.11 (Feb 2008): 85–102.Stuart J. H. Graham, Matthew John Higgins Timing New Drug Introductions: The Roles of Regulatory Rules and Firms' Complementary Assets, (Jan 2008).Yu Yu, Sachin Gupta Pioneering Advantage in Generic Drug Competition, (Jan 2008).Jorge Gonzalez, Catarina Sismeiro, Shantanu Dutta, Philip Stern Can Branded Drugs Benefit from Generic Entry? Switching to Non-Bioequivalent Molecules and the Role of Physician Response to Detailing and Prices, (Jan 2008).Joseph P Cook, John A Vernon, Richard Manning Pharmaceutical Risk-Sharing Agreements, 26, no.77 (Jan 2008): 551–556.Haiden A Huskamp, Julie M Donohue, Catherine Koss, Ernst R Berndt, Richard G Frank Generic Entry, Reformulations and Promotion of SSRIs in the US, 26, no.77 (Jan 2008): 603–616.Dennis W. Carlton, Ken Heyer The Year in Review: Economics at the Antitrust Division, 2006–2007, 31, no.22 (Oct 2007): 121–137.Michael A. Salinger, Pauline M. Ippolito, Joel L. Schrag Economics at the FTC: Pharmaceutical Patent Dispute Settlements and Behavioral Economics, 31, no.22 (Nov 2007): 85–105.Frank R. Lichtenberg IMPORTATION AND INNOVATION, 16, no.66 (Sep 2007): 403–417.Cori Hayden A Generic Solution? Pharmaceuticals and the Politics of the Similar in Mexico Hayden, 48, no.44 (Jul 2015): 475–495.Yi Qian Do National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978–2002, 89, no.33 (Aug 2007): 436–453.Rodrigo A. Cerda Endogenous innovations in the pharmaceutical industry, 17, no.44 (May 2007): 473–515.David Reiffen, Michael R. Ward ‘Branded Generics’ as a strategy to limit cannibalization of pharmaceutical markets, 28, no.4-54-5 (Jan 2007): 251–265.Henry G. Grabowski, David B. Ridley, Kevin A. Schulman Entry and competition in generic biologics, 28, no.4-54-5 (Jan 2007): 439–451.Panos Kanavos, Joan Costa Font, Alistair McGuire Product differentiation, competition and regulation of new drugs: the case of statins in four European countries, 28, no.4-54-5 (Jan 2007): 455–465.Henry G. Grabowski, Margaret Kyle Generic competition and market exclusivity periods in pharmaceuticals, 28, no.4-54-5 (Jan 2007): 491–502.ALLEN N. BERGER, ASTRID A. DICK Entry into Banking Markets and the Early-Mover Advantage, 39, no.44 (Jun 2007): 775–807.Kurt R. Brekke, Ingrid Königbauer, Odd Rune Straume Reference pricing of pharmaceuticals, 26, no.33 (May 2007): 613–642.Laurent Granier, Sébastien Trinquard Pseudo-génériques et fusions « stratégiques » dans l’industrie du médicament, , no.117117 (Mar 2007): 23–50.Joan-Ramon Borrell Pricing and patents of HIV/AIDS drugs in developing countries, 39, no.44 (Mar 2007): 505–518.Margaret K. Kyle Pharmaceutical Price Controls and Entry Strategies, 89, no.11 (Feb 2007): 88–99.Kyle Bagwell Chapter 28 The Economic Analysis of Advertising, (Jan 2007): 1701–1844.Panos Kanavos Do generics offer significant savings to the UK National Health Service?, 23, no.11 (Dec 2006): 105–116.Antonio Cabrales, Sergi Jimenez-Martin The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?, (Jan 2007).Pierre Moïse, Elizabeth Docteur Pharmaceutical Pricing and Reimbursement Policies in Sweden, (Jan 2007).Kurt Richard Brekke, Tor Helge Holmas, Odd Rune Straume Regulation, Generic Competition and Pharmaceutical Prices: Theory and Evidence from a Natural Experiment, (Jan 2007).Iván Moreno-Torres, Jaume Puig-Junoy, Joan-Ramon Borrell Generic Entry into a Regulated Pharmaceutical Market, (Jan 2007).Ya-Chen Tina Shih, Nebiyou B Bekele, Ying Xu Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients, 25, no.1010 (Jan 2007): 843–862.Desmond Sheridan, Jim Attridge The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine, 24, no.S2S2 (Feb 2013): 35–54.Srikanth Paruchuri, Atul Nerkar, Donald C. Hambrick Acquisition Integration and Productivity Losses in the Technical Core: Disruption of Inventors in Acquired Companies, 17, no.55 (Oct 2006): 545–562.Dag Morten Dalen, Steinar Strøm, Tonje Haabeth Price regulation and generic competition in the pharmaceutical market, 7, no.33 (Sep 2006): 204–211.Margaret K. Kyle The role of firm characteristics in pharmaceutical product launches, 37, no.33 (Sep 2006): 602–618.Henry Grabowski Patents and New Product Development in the Pharmaceutical and Biotechnology Industries, (Dec 2009): 533–546.Y. Richard Wang Price competition in the chinese pharmaceutical market, 6, no.22 (Jun 2006): 119–129.Sara Fisher Ellison, Catherine Wolfram Coordinating on lower prices: pharmaceutical pricing under political pressure, 37, no.22 (Jun 2006): 324–340.Joshua W. Devine, Richard R. Cline, Joel F. Farley Follow-on Biologics: Competition in the Biopharmaceutical Marketplace, 46, no.22 (Mar 2006): 193–204.John A. Pearce How companies can preserve market dominance after patents expire, 39, no.11 (Feb 2006): 71–87.Atanu Saha, Henry Grabowski, Howard Birnbaum, Paul Greenberg, Oded Bizan Generic Competition in the US Pharmaceutical Industry, 13, no.11 (Jan 2007): 15–38.Kurt R. Brekke, Michael Kuhn Direct to consumer advertising in pharmaceutical markets, 25, no.11 (Jan 2006): 102–130.Aidan Hollis How do Brands’ “Own Generics” Affect Pharmaceutical Prices?, 27, no.44 (Dec 2005): 329–350.Zaheer Ud din Babar, Mohamed Izham Mohamed Ibrahim, Nadeem Irfan Bukhari Medicine Utilisation and Pricing in Malaysia: The Findings of a Household Survey, 3, no.11 (Jul 2016): 47–61.P. Kanavos, J. Costa-Font Pharmaceutical parallel trade in Europe: stakeholder and competition effects, 20, no.4444 (Oct 2005): 758–798.Gregory S. Crawford, Matthew Shum Uncertainty and Learning in Pharmaceutical Demand, 73, no.44 (Jul 2005): 1137–1173.Atul Nerkar, Srikanth Paruchuri Evolution of R&D Capabilities: The Role of Knowledge Networks Within a Firm, 51, no.55 (May 2005): 771–785.By Carmelo Giaccotto , Rexford E. Santerre , and John A. Vernon Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry Giaccotto/Santerre/Vernon, 48, no.11 (Jul 2015): 195–214.David Reiffen, Michael R. Ward Generic Drug Industry Dynamics, 87, no.11 (Feb 2005): 37–49.Ya-Chen Tina Shih, Shu Han, Scott B. Cantor Impact of Generic Drug Entry on Cost-Effectiveness Analysis, 25, no.11 (Jul 2016): 71–80.David S. Evans, Michael A. Salinger The Role of Cost in Determining When Firms Offer Bundles, (Jan 2005).David Reiffen, Michael R. Ward 'Branded Generics' as a Strategy to Limit Cannibalization of Pharmaceutical Markets, (Jan 2005).Alan C. Marco Patent Protection, Creative Destruction, and Generic Entry in Pharmaceuticals: Evidence from Patent and Pricing Data, (Jan 2005).Mattias Ganslandt, Keith E. Maskus Parallel imports and the pricing of pharmaceutical products: evidence from the European Union, 23, no.55 (Sep 2004): 1035–1057.Joel Lexchin The effect of generic competition on the price of brand-name drugs, 68, no.11 (Apr 2004): 47–54.Steven N. Wiggins, Robert Maness Price Competition in Pharmaceuticals: The Case of Anti-infectives, 42, no.22 (Apr 2004): 247–263.Steven J. Davis , Kevin M. Murphy , and Robert H. Topel Entry, Pricing, and Product Design in an Initially Monopolized Market Davis et al., 112, no.S1S1 (Jul 2015): S188–S225.Eduardo S. Schwartz Patents and R&D as Real Options, 33, no.11 (Feb 2004): 23–54.Andrew Ching Some Observations in the U.S. Prescription Drug Market after Patent Expiration During the 80s, (Jan 2004).Jeff Jianfei Guo, Christina M.L. Kelton, Margaret K. Pasquale, Jennie Zimmerman, Amit Patel, Pamela C. Heaton, Robert J. Cluxton Price and Market-Share Competition of Anti-Ulcer Gastric Medications in the Ohio Medicaid Market, 18, no.55 (Jan 2004): 271–282.Jayanta Bhattacharya and William B. Vogt A Simple Model of Pharmaceutical Price Dynamics Bhattacharya/Vogt, 46, no.22 (Jul 2015): 599–626.Soonman Kwon Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing, 57, no.33 (Aug 2003): 529–538.Mats Ekelund, Björn Persson Pharmaceutical Pricing in a Regulated Market, 85, no.22 (May 2003): 298–306.David Reiffen, Michael Robert Ward Generic Drug Industry Dynamics, (Jan 2003).Antonio Cabrales Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy, (Jan 2003).Aidan Hollis The importance of being first: evidence from Canadian generic pharmaceuticals, 11, no.88 (Jan 2002): 723–734.Michael B. Ward, Jay P. Shimshack, Jeffrey M. Perloff, J. Michael Harris Effects of the Private‐Label Invasion in Food Industries, 84, no.44 (Nov 2002): 961–973.Davina C. Ling , Ernst R. Berndt , and Margaret K. Kyle Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales Ling/Berndt/Kyle, 45, no.S2S2 (Jul 2015): 691–723.Ya-Chen Tina Shih, Manishi Prasad, Bryan R. Luce The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: A microeconomic analysis, 24, no.44 (Apr 2002): 701–716.Eduardo P.S. Fiuza, Marcos de Barros Lisboa Credence Goods and Market Power: An Econometric Study on the Brazilian Pharmaceutical Industry, (Jan 2002).Sanghoon Ahn Competition, Innovation and Productivity Growth: A Review of Theory and Evidence, (Jan 2002).Darryl R. Biggar Competition and Regulation Issues in the Pharmaceutical Industry, (Jan 2002).Charles King Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs, (Jan 2002).Giulio Bottazzi, Giovanni Dosi, Marco Lippi, Fabio Pammolli, Massimo Riccaboni Innovation and corporate growth in the evolution of the drug industry, 19, no.77 (Jul 2001): 1161–1187.J. C. H. Jones, Tanya Potashnik, Anming Zhang Patents, brand-generic competition and the pricing of ethical drugs in Canada: some empirical evidence from British Columbia, 1981-1994, 33, no.77 (Jun 2001): 947–956.Albert A. Okunade The Impact of 1990 Medicaid Drug Rebates Policy on Access to Prescriptions, 12, no.33 (Oct 2008): 33–51.Sara Fisher Ellison, Christopher M. Snyder Countervailing Power in Wholesale Pharmaceuticals, (Jan 2001).By Patricia M. Danzon and Li‐Wei Chao Does Regulation Drive out Competition in Pharmaceutical Markets? Danzon & Chao, 43, no.22 (Jul 2015): 311–358.Fiona M. Scott Morton Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry, 18, no.77 (Oct 2000): 1085–1104.Douglas Lundin Moral hazard in physician prescription behavior, 19, no.55 (Sep 2000): 639–662.John Hudson Generic take-up in the pharmaceutical market following patent expiry, 20, no.22 (Jun 2000): 205–221.Patricia M. Danzon, Li-Wei Chao Cross-national price differences for pharmaceuticals: how large, and why?, 19, no.22 (Mar 2000): 159–195.F.M. Scherer Chapter 25 The pharmaceutical industry, (Jan 2000): 1297–1336.Henry G. Grabowski, John M. Vernon Effective patent life in pharmaceuticals, 19, no.1/21/2 (Jan 2000): 98.Jorge Mestre Ferrándiz The impact of generic goods in the pharmaceutical industry, 8, no.77 (Nov 1999): 599–612.Peter W. Roberts Product innovation, product-market competition and persistent profitability in the U.S. pharmaceutical industry, 20, no.77 (Jul 1999): 655–670.Morton I. Kamien, Israel Zang Virtual Patent Extension by Cannibalization, 66, no.11 (Jul 1999): 117–131.By John A. Rizzo Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs Rizzo, 42, no.11 (Jul 2015): 89–116.Gregory S. Crawford, Matthew Shum Uncertainty and Experimentation in Pharmaceutical Demand: Anti-Ulcer Drugs, (Jan 1999).Z. John Lu, William S. Comanor Strategic Pricing of New Pharmaceuticals, 80, no.11 (Feb 1998): 108–118.PATRICIA M. DANZON Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU, 4, no.33 (May 2011): 301–322.Dennis C. Mueller First-mover advantages and path dependence, 15, no.66 (Oct 1997): 827–850.Madhu Agrawal, Nimish Thakkar Surviving patent expiration: strategies for marketing pharmaceutical products, 6, no.55 (Oct 1997): 305–314.Pharmaceutical Pricing at the Change of Millennia, 1, no.11 (Aug 1997): 99–112.Henry Grabowski, C.Daniel Mullins Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions, 45, no.44 (Aug 1997): 535–544.Steven W. Kopp, Mary Jane Sheffet The Effect of Direct-to-Consumer Advertising of Prescription Drugs on Retail Gross Margins: Empirical Evidence and Public Policy Implications, 16, no.22 (Dec 2018): 270–276.By Richard L Manning Products Liability and Prescription Drug Prices in Canada and the United States Manning, 40, no.11 (Jul 2015): 203–244.Henry G. Grabowski, John M. Vernon Longer Patents for Increased Generic Competition: the Waxman-Hatch Act after One Decade, (Jan 1997).Chutima Suraratdecha A model of state-level prescription drug expenditures in the USA, 3, no.55 (May 1996): 289–292.Mick Kolassa Pharmaceutical Pricing at the Change of Millennia, 10, no.2-32-3 (Dec 2011): 109–120.Joseph A. Dimasi, Henry G. Grabowski, John Vernon R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry, 2, no.22 (Jul 1995): 201–219.Thomas A. Abbott Regulating Pharmaceutical Prices, (Jan 1995): 105–141.Ann-Marie Craig, Mo Malek Market structure and conduct in the pharmaceutical industry, 66, no.22 (Jan 1995): 301–337.William T. Robinson, Gurumurthy Kalyanaram, Glen L. Urban First-mover advantages from pioneering new markets: A survey of empirical evidence, 9, no.11 (Feb 1994): 1–23.Henry G Grabowski, John M Vernon Returns to R&D on new drug introductions in the 1980s, 13, no.44 (Jan 1994): 383–406.F. M Scherer Pricing, Profits, and Technological Progress in the Pharmaceutical Industry, 7, no.33 (Aug 1993): 97–115.